Auron Therapeutics, Inc.

Auron Therapeutics, Inc.

is a clinical-stage biotechnology company based in Newton, Massachusetts. Founded by Dr. Kate Yen, Ph.D., the company focuses on developing first-in-class targeted therapies that utilize cell-state plasticity to transform malignant cells into normal, functioning cells. Auron's mission is to cure cancer by reactivating cellular programs that promote tumor cell maturation and differentiation. The company’s proprietary AURIGINTM platform employs AI and machine learning to analyze cell states and identify novel drug targets. Auron is advancing its lead candidate, AUTX-703, an oral KAT2A/B degrader, which has received FDA clearance for Phase 1 clinical development in hematological malignancies, specifically acute myeloid leukemia. Auron aims to build a pipeline of differentiation therapies that reprogram cancer cells, targeting both solid tumors and hematologic malignancies, as well as addressing inflammatory diseases.